ArticlePharmaceutics2024

Safety and Tolerability of KIO-101 Eye Drops in Healthy Volunteers and Patients with Ocular Surface Disease-A Phase I Study.

Doreen Schmidl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.